Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.

Molecular cancer research : MCR - 1 Jun 2009

Leung Elaine Lai-Han, Tam Issan Yee-San, Tin Vicky Pui-Chi, Chua Daniel Tsin-Tien, Sihoe Alan Dart-Loon, Cheng Lik-Cheung, Ho James Chung-Man, Chung Lap-Ping, Wong Maria Pik

Abstract excerpt

Molecular-targeted therapy using tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) is an effective therapy for non-small cell lung cancer that harbor EGFR mutations. This study aimed to investigate the role of Src, a close EGFR associator, as a drug target in NSCLC cells with different EGFR genomic statuses. Src inhibition was achieved using 4-(4'-Phenoxyanilino)-6,7-dimethoxyquinazolinee...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Movement
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Neoplasm Invasiveness

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to RNA, Small Interfering

Share to src-Family Kinases

Source

Identifiers

PMID: 19491201
DOI: 10.1158/1541-7786.MCR-09-0003

Genes

EGFR
SKI
SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.PMID 19491201Read ↗

SRC: A Century of Science Brought to the ClinicSemantic proximity Read ↗

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Semantic proximity Read ↗

Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancerSemantic proximity Read ↗

SRC: Regulation, Role in Human Carcinogenesis and Pharmacological InhibitorsSemantic proximity Read ↗

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated<i>EGFR</i>gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cellsSemantic proximity Read ↗

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.Semantic proximity Read ↗

Src Continues Aging: Current and Future Clinical DirectionsSemantic proximity Read ↗

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So FarSemantic proximity Read ↗

Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.Semantic proximity Read ↗

Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.Semantic proximity Read ↗

Peruvoside is a new Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathwaysSemantic proximity Read ↗

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.